Craving and opioid use disorder: A scoping review

Kleykamp, Bethea A.; Santis, Marta De; Dworkin, Robert H.; Huhn, Andrew S.; Kampman, Kyle M.; Montoya, Iván D.; Preston, Kenzie L.; Ramey, Tanya; Smith, Shannon M.; Turk, Dennis C.; Walsh, Robert J.; Weiss, Roger D.; Strain, Eric C.

doi:10.1016/j.drugalcdep.2019.107639

Cited by 42 publications

(22 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifth, the current study used only VAS as a subjective evaluation to assess craving for METH, which may lead to reporting bias and social desirability bias, especially among subjects undergoing compulsory rehabilitation in this study. Although VAS has been commonly used for craving assessment in multiple studies ( Rosenberg, 2009 ; Kleykamp et al., 2019 ), future research could apply objective methods (e.g., electroencephalograph) to improve the reliability of craving measurement ( Parvaz et al., 2016 ). Finally, the use of 16S rRNA sequencing only allowed us to identify taxa down to the genus level, and specific variation at the species level was therefore not evaluated.…”

Section: Discussionmentioning

confidence: 99%

Altered Fecal Microbiota Correlated With Systemic Inflammation in Male Subjects With Methamphetamine Use Disorder

Deng

Song

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Methamphetamine use disorder (MUD) is a major public health problem worldwide with limited effective treatment options. Previous studies have reported methamphetamine-associated alterations in gut microbiota. A potential role of gut microbiota in regulating methamphetamine-induced brain dysfunction through interactions with the host immune system has been proposed, but evidence for this hypothesis is limited. The present study aimed to investigate the alterations in the fecal microbiota and explore its relationship with systemic inflammation in MUD. Fecal samples were obtained from 26 male subjects with MUD and 17 sex- and age- matched healthy controls. Fecal microbial profiles were analyzed by 16S rRNA sequencing. Plasma inflammatory markers were measured using enzyme-linked immunosorbent assay. Associations between fecal microbiota, systemic inflammatory markers and clinical characteristics were examined by Spearman partial correlation analysis while controlling for possible confounders. Compared with healthy controls, individuals with MUD showed no difference in fecal microbial diversity, but exhibited differences in the relative abundance of several microbial taxa. At the genus level, a higher abundance of Collinsella, Odoribacter and Megasphaera and lower levels of Faecalibacterium, Blautia, Dorea and Streptococcus were detected in subjects with MUD. More importantly, altered fecal microbiota was found to be correlated with plasma levels of CRP, IL-2, IL-6 and IL-10. The order Lactobacillales, exhibiting lower abundance in participants with MUD, was positively related to the duration of methamphetamine abstinence and the plasma level of anti-inflammatory cytokine IL-10. This study is the first to provide evidence for a link between altered fecal microbiota and systemic inflammation in MUD. Further elucidation of interactions between gut microbiota and the host immune system may be beneficial for the development of novel therapeutic approaches for MUD.

show abstract

Section: Discussionmentioning

confidence: 99%

Altered Fecal Microbiota Correlated With Systemic Inflammation in Male Subjects With Methamphetamine Use Disorder

Deng

Song

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Reuse and relapse in opioid use disorder (OUD) is driven in part by craving-the fluctuating, intense, and specific desire for the drug. Craving is an extensively studied and wellestablished predictor of drug use [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Yet, we still lack a precise understanding of how the psychological experience of craving translates to pursuit of the drug over other valuable, and healthier, alternatives.…”

Section: Introductionmentioning

confidence: 99%

A neuroeconomic signature of opioid craving: How fluctuations in craving bias drug-related and nondrug-related value

Biernacki

López-Guzmán

Messinger

et al. 2021

Neuropsychopharmacol.

View full text Add to dashboard Cite

How does craving bias decisions to pursue drugs over other valuable, and healthier, alternatives in addiction? To address this question, we measured the in-the-moment economic decisions of people with opioid use disorder as they experienced craving, shortly after receiving their scheduled opioid maintenance medication and ~24 h later. We found that higher cravers had higher drug-related valuation, and that moments of higher craving within-person also led to higher drug-related valuation. When experiencing increased opioid craving, participants were willing to pay more for personalized consumer items and foods more closely related to their drug use, but not for alternative “nondrug-related” but equally desirable options. This selective increase in value with craving was greater when the drug-related options were offered in higher quantities and was separable from the effects of other fluctuating psychological states like negative mood. These findings suggest that craving narrows and focuses economic motivation toward the object of craving by selectively and multiplicatively amplifying perceived value along a “drug relatedness” dimension.

show abstract

“…Furthermore, opioid craving was assessed as an index of opioid misuse severity, using a visual analog scale (VAS-craving). The VAS-craving was a quantitative measurement where the participant quantifies their current state of craving by marking a point on a scale form 0-100, with 0 as no craving at all and 100 as the most severe craving imaginable [62]. VAS-craving measurement was commonly used in addiction medicine to monitor craving severity [62].…”

Section: Opioid Misusementioning

confidence: 99%

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder

Schellekens

Veldman

Suranto

et al. 2021

JCM

View full text Add to dashboard Cite

Patients with chronic non-cancer pain (CNCP) often use opioids for long periods of time. This may lead to opioid use disorder (OUD) and psychiatric symptoms: mainly depression and anxiety. The current study investigated the effect of buprenorphine/naloxone (BuNa) rotation on opioid misuse, craving, psychiatric symptoms and pain in patients with CNCP and OUD. Forty-three participants with CNCP and OUD were converted from a full mu-receptor agonist opioid (mean morphine equivalent dose: 328.3 mg) to BuNa, in an inpatient setting. Opioid misuse, craving, co-occurring psychiatric symptoms, and pain perception were determined at baseline and after a two-month follow-up, using the following self-report questionnaires: Current Opioid Misuse Measurement (COMM), Visual Analog Scale (VAS-craving and VAS-pain) and Depression, Anxiety and Stress Scale (DASS), respectively. VAS-craving and VAS-pain were also determined immediately after conversion. A total of 37 participants completed the protocol. The mean COMM decreased from 17.1 to 6.7 (F = 36.5; p < 0.000), the mean VAS-craving decreased from 39.3 to 5.3 (−86.6%; F = 26.5, p < 0.000), the mean DASS decreased from 12.1 to 6.6 (F = 56.3, p < 0.000), and the mean VAS-pain decreased from 51.3 to 37.2 (−27.4%, F = 3.3; p = 0.043). Rotation to BuNa in patients with CNCP and OUD was accompanied by reductions in (i) opioid misuse, (ii) opioid craving, (iii) the severity of co-occurring psychiatric symptoms, and (iv) self-reported pain. BuNa as opioid agonist treatment may therefore be a beneficial strategy in CNCP patients with OUD. The limited sample size and the observational nature of this study underline the need for the replication of the current findings in large-scale, controlled studies.

show abstract

Craving and opioid use disorder: A scoping review

Cited by 42 publications

References 133 publications

Altered Fecal Microbiota Correlated With Systemic Inflammation in Male Subjects With Methamphetamine Use Disorder

Altered Fecal Microbiota Correlated With Systemic Inflammation in Male Subjects With Methamphetamine Use Disorder

A neuroeconomic signature of opioid craving: How fluctuations in craving bias drug-related and nondrug-related value

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder

Contact Info

Product

Resources

About